MarR is the dedicated autorepressor of the marRAB operon found in seven genera of the Enterobacteraceae. The MarA transcriptional regulator directly activates numerous genes involved in multidrug resistance and other environmental responses. MarR is inactivated by certain phenolic ligands, such as salicylate, by an unknown mechanism. Our recent work has shown that several amino acid residues of Escherichia coli MarR affecting ligand binding are located between the dimerization and DNA-binding domains. To further characterize the ligand-binding region of MarR, we have now examined 7 point mutants generated by random mutagenesis and 11 site-directed alanine replacement mutants for inactivation by three ligands: salicylate, 2,4-dinitrophenol, and plumbagin. Inactivation of MarR was quantitated in intact cells by loss of MarR-mediated repression of a chromosomal mar-lacZ transcriptional fusion. The results showed that most of the residues important for ligand effectiveness lay in the a1 and a2 helices of MarR, between the putative DNA-binding domain and the dimerization domain of MarR, reinforcing our earlier findings. Moreover, the three ligands had different, but overlapping, sets of residues impacting their effects on MarR.
Introduction
MarR is a protein which autorepresses the marRAB operon found in Escherichia coli and related enteric bacteria by binding within the E. coli mar promoter region (Martin & Rosner, 1995) . The MarA protein also encoded in this operon (and hence regulated by MarR) is a transcriptional activator that targets many genes affecting stress responses and multidrug resistance, including those for the AcrAB/TolC multidrug efflux pump (Alekshun & Levy, 1997; Martin & Rosner, 2002) . Multidrug resistance can develop in clinical strains when the MarR protein is inactivated by mutations (Maneewannakul & Levy, 1996; Oethinger et al., 1998; Linde et al., 2000; Warner et al., 2013) or in the presence of certain phenolic ligands originating from plants or bacteria (salicylate and plumbagin; 2,3-dihydroxybenzoate; Alekshun & Levy, 1999a; Chubiz & Rao, 2010) , or of synthetic origin (2,4-dinitrophenol; Alekshun & Levy, 1999a) . MarR from E. coli is the prototype for the 'MarR family' of structural homologs that have little primary amino acid sequence identity (Kumarevel et al., 2008; Wilke et al., 2008) .
The present study was designed to identify residues of E. coli MarR involved in its inactivation by different ligands. Our recent work shows that alanine replacement mutations of residues in the original 'salicylate sites' suggested by the E. coli MarR-salicylate co-structure (Alekshun et al., 2001) have in fact no effect on salicylate binding . Mutations R16A, D26N, and K44A, in a region similar to that for salicylate binding in the MarR structural homolog MTH313 from the archaeon Methanobacterium thermoautotrophicum (Saridakis et al., 2008) , reduce binding of purified MarR protein to both salicylate and 2,4-dinitrophenol, and mutation H19A reduces binding to 2,4-dinitrophenol, suggesting that these residues are involved in ligand binding .
We now continue the mutational approach, looking for additional residues important for inactivation of MarR by salicylate and 2,4-dinitrophenol. We also now include a third ligand, plumbagin. We took two routes to find such residues. One involved random mutagenesis of marR followed by screening for failure to be induced by salicylate. The other involved site-directed mutagenesis of additional specific residues of MarR predicted by the structure of the MTH313/salicylate complex to be involved in binding of E. coli MarR to salicylate (Saridakis et al., 2008) .
Materials and methods

Strains and plasmids
Strains and plasmids are shown in Table 1 . Construction details are provided in Supporting Information, Data S1. Derivatives of pET28a encoding wild type (WT), R16A, D26N, and G95S versions of MarR were generously provided by Val erie Duval .
Random mutagenesis
The template for error-prone DNA polymerase Mutazyme II (originally Stratagene; now Agilent GeneMorph II) was pAC-MarR-WT (Alekshun & Levy, 1999a, b) , and primer pairs were ACmutF (CAGCTATGACCATGATTACGA ATTC) and ACmutR (GTTGTTGCCATTGCTGC). These primers were complementary only to sequences in the vector, allowing mutagenesis of all of marR including the stop codon. The PCR amplification was for 5 or 7 cycles (PCR5 and PCR7), giving 2.7 or 4.4 doublings, respectively. The number of doublings was determined as follows: marR DNA standards of known amounts were electrophoresed together with samples of the PCR5 and PCR7 products on the same agarose gel to quantify the final amounts of PCR5 and PCR7; then, the number of doublings (d) was found using the equation d = log [(F-I)/I]/0.3, where I was the initial ng of marR template DNA, and F was the final ng of marR PCR product. After further amplification with high-fidelity Phusion DNA polymerase (New England Biolabs), the mutated marR For final quantitative analyses, mutations were later transferred to vector pET28a using PCR, as described earlier.
As one mutant marR ('3AA') contained three amino acid substitutions, M20T, V21F, and A105T, the first two mutations were recreated singly in pET28a by site-directed mutagenesis (see below); the single A105T mutation could not be obtained. Presumably, our random mutagenesis did not find all mutations that might affect the inactivation of MarR by ligands.
Site-directed mutagenesis
Conversion to alanine by site-directed mutagenesis used either the overlap extension (Ho et al., 1989) or megaprimer (Colosimo et al., 1999) PCR method with appropriate mutant primers, followed by cloning into pET28a, as described in Data S1. The single substitutions M20T and V21F were created in the same fashion.
Quantitation of response of MarR mutants to ligands by LacZ assays
The LacZ activity of the mar promoter transcriptional fusion mar-lacZ was measured in host SPC105LMDmarR-DemrR for all mutations borne on pET28a-MarR or on pMPM-MarR. In the case of mutants of pET28a-MarR, one of two other plasmids was also present. In the 'pACT7Sp System', used for MarR mutants repressing less than or the same as WT, pACT7Sp (encoding T7 RNA polymerase) was present and IPTG was 0.1 lM IPTG. In the 'F'LacIQ System', used to reduce the amounts of MarR protein for MarR mutants repressing better than wild type, pACT7Sp was replaced by F'LacIQ and no IPTG was added. Methods for growth of cells and for LacZ assays are detailed in Data S1. For each ligand, LacZ data were normalized by dividing LacZ values for the WT or mutant MarR by that for the vector alone.
Apparent Ks in vivo for ligand binding to MarR
The apparent Ks (dissociation constant) was estimated solely from LacZ assays performed without and with ligand and was independent of the total amount of MarR in the cell or its affinity for DNA. The rationale and equations are presented in Data S1. The number of independent determinations for Ks was WT, 7; all others including WT*, 3-7.
Results and discussion
Repression of mar promoter by chromosomal EmrR
EmrR (also known as MprA) represses the emrRAB multidrug efflux operon by binding to a site overlapping the promoter (Xiong et al., 2000) . On a plasmid, emrR was also found to repress marRAB (Sulavik et al., 1995) . Earlier works had reported that chromosomally produced EmrR had no detectable effect on a mar promoter fusion in a host deleted for marRAB (Sulavik et al., 1995; Martin & Rosner, 1997) . However, when we compared the LacZ activities in WT, DmarR, DemrR, and DmarRDemrR derivatives of our host SPC105LM, we found that the mar-lacZ promoter reporter was repressed 2.5-fold by chromosomal EmrR, while chromosomal MarR repressed it 14-fold. The two proteins MarR and EmrR together repressed 26-fold and thus appeared to act synergistically rather than additively. For simplicity, we have used a strain deleted for both marR and emrR in our ligand comparison studies.
Selection of marR mutants by random mutagenesis
In the first approach to finding residues of MarR involved in the ligand response, we performed error-prone PCR mutagenesis of marR using a nonproofreading DNA polymerase (see Materials and methods). Transformants were picked onto XGal plates containing IPTG and salicylate, where colonies producing WT MarR (inactivated by salicylate, no longer repressing mar-lacZ) became blue, while those producing nonresponding or possibly superrepressor mutant MarRs remained white. Of the 380 transformants screened from two independent PCRs and from several independent transformations, about 17% (PCR5) or 43% (PCR7) had nonfunctional MarR (were blue even without salicylate), indicating effective mutagenesis. The sought white colonies represented about 1.5% to 3% of the total.
In this way, we found four marR mutant nonresponders: single mutants N22K, D26A, S48P, and triple mutant M20T-V21F-A105T. The genes N22K, D26A, and S48P were each transferred via PCR and cloning to create individual pET28a-MarR versions for quantitative analyses. The same was performed for the genes for M20T and V21F, created individually by site-directed mutagenesis. Finally, the genes for super-repressors D26N and G95S, also obtained by random mutagenesis but in a previous study (Alekshun & Levy, 1999b) , had been cloned earlier .
Selection of marR mutants by site-directed mutagenesis
The second approach to finding nonresponding mutants of MarR was based on the MarR structural homolog MTH313. Its structure with salicylate has been published, and the two salicylate molecules are located differently from any of the four salicylates in the MarR structure (Saridakis et al., 2008) . In that work, 13 residues of MarR with positions that appeared to correspond to those of salicylate binding site 1 in MTH313 were identified (Saridakis et al., 2008) . In an earlier work, we described results for salicylate and 2,4-dinitrophenol with mutations in four of these residues, R16A, H19A, D26N, and K44A . We now converted eight additional residues to alanine by site-directed mutagenesis: Q23A, K25A, L29A, F43A, C47A, R50A, C51A, and H112A.
Determination of assay conditions which best measured response of MarR to ligand
We used strain SPC105LMDmarRDemrR to quantitate the ability of plasmid-encoded mutant marR genes (regulated by the T7lac promoter of pET28a-MarR) to repress marlacZ in the absence and presence of ligand. For most mutants, the 'pACT7Sp System' was used (see Materials and methods). In this system, IPTG induced synthesis of both T7 RNA polymerase (from pACT7Sp) and MarR (from pET28a-MarR, for which T7 RNA polymerase acted on the LacI-repressed T7 promoter). We found that if too much WT MarR was produced, no induction by salicylate occurred. Specifically, at ≥ 1 lM IPTG, the synthesis of WT MarR was such that over 95% of DNA was repressed [r < 0.05, where r = (LacZ with MarR)/(LacZ without MarR)], and salicylate was unable to reverse this repression, presumably because excess free WT MarR was still present. At IPTG ≤ 0.1 lM, when about 87% of DNA was repressed (r = 0.13), good induction by salicylate could be seen. Therefore, in the 'pACT7Sp System', we chose to measure the response to ligand at 0.1 lM IPTG. For hyperactive mutants (repressing better than wild type), to see the inducing effect of ligands, it was necessary to decrease MarR levels. Therefore, the 'F'LacIQ System' was used, in which pACT7Sp was replaced by F'LacIQ, encoding additional repressor LacI, and no IPTG was added. Unexpectedly, even in the absence of pACT7Sp encoding T7 polymerase, enough MarR was produced to repress mar-lacZ well; F'LacIQ reduced that level of MarR about 1.6-fold.
In the fully derepressed host (harboring vector pET28a and making no MarR) in the pACT7Sp System, the mar-lacZ promoter fusion was quite active: The average LacZ activity was 16000 AE 1500 (SD) Miller units.
Effect of salicylate, 2,4-dinitrophenol, and plumbagin on the ability of MarR mutants to repress mar-lacZ
We measured LacZ activity in cells containing no MarR, WT MarR, or mutant MarR, without or with each of the three ligands, asking whether a mutant was resistant to a ligand (repression by a mutant MarR would persist in the presence of the ligand). The primary data are shown in Fig. 1 , where expression of mar-lacZ is normalized to its expression in the absence of MarR (and of EmrR). The results for mutants that either repressed similarly to WT MarR or induced little with ligand are the easiest to interpret. For example, C47A was resistant only to plumbagin; H19A, K25A, and L29A were resistant to 2,4-dinitrophenol; D26A was resistant to salicylate and 2,4-dinitrophenol, while N22K, S48P, and 3AA (which was M20T-V21F-A105T) were resistant to all three ligands.
For a more detailed semi-quantitative analysis, we corrected for the inherent differences in repressive abilities of the various MarR mutants by calculating an 'apparent Ks' representing an estimation of the dissociation constant for ligand binding to MarR in vivo (see Data S1). Results of this analysis are shown in Table 2 , displayed as fold resistance to a ligand (compared with WT).
The fold resistance of a given mutant MarR to ligand was not uniform for all ligands ( Fig. 1 and Table 2 ). All of the random mutants were highly resistant to salicylate, which was not surprising as they had been chosen initially for their failure to be inactivated by salicylate. All random mutants also had some resistance to 2,4-dinitrophenol. Only the mutants N22K, S48P, and 3AA had good plumbagin resistance and were the only mutants to show high resistance to all three ligands. Of the 11 mutants in total chosen based on the salicylate site 1 of MTH313, less than half had resistance to salicylate. In fact, the highest and most frequent resistance was that to 2,4-dinitrophenol, found in eight mutants. Strikingly, C47A was resistant only to plumbagin and at a high level. Three site-directed mutants, Q23A, C51A, and H112A, were unaltered in response to any ligand.
Thus, the MarR model based on the MTH313/salicylate co-structure was rather poor in identifying residues important for inactivation of MarR by salicylate, but it clearly did find residues important for the other two ligands. Taken together, our data show that the three ligands, whose rather diverse structures are shown in Supporting Information, Fig. S1 , have separate but overlapping sites in MarR influencing inactivation by ligand.
Proteins for five of the mutants analyzed here have been purified and tested for binding to salicylate and 2,4-dinitrophenol in our earlier study . H19A and K44A displayed reduced binding to 2,4-dinitrophenol, and D26N displayed reduced binding to salicylate and 2,4-dinitrophenol, in agreement with the presently observed resistance to those ligands in vivo (Table 2) . However, some of the present results were not in accordance with the previous study: Now, we found no resistance of K44A to salicylate and only a modest resistance by R16A to salicylate and 2,4-dinitrophenol (Table 2) , while previously we had observed notable decreases in binding for the purified proteins . The in vivo (LacZ) and in vitro (purified protein) method for determining binding of ligand each has advantages and disadvantages. The in vivo (present) method reflects a physiological reality but does not directly measure binding; binding is estimated only approximately by an 'apparent Ks', the calculation of which makes several assumptions (see Data S1). The in vitro (earlier) method measures ligand binding to purified MarR protein in buffer; this method is more defined but may not reproduce the intracellular environment. Results with G95S, the only nonresponder mutation isolated thus far which is located near the putative DNAbinding domain of MarR, also differed between the two methods. The earlier study using purified MarR found no decrease in binding for either salicylate or 2,4-dinitrophenol and attributed the apparent salicylate resistance phenotype of the G95S mutant in LacZ assays in vivo to the known higher affinity of this 'super-repressor' mutant for DNA . We confirmed the apparent resistance in vivo to salicylate and 2,4-dinitrophenol, but we saw a normal induction of G95S by plumbagin (Table 2) , which would not be expected from a superrepressor explanation.
To further pursue this question, we used plasmid pMPM-MarR, in which MarR synthesis was inducible by arabinose (see Data S1). When pMPM-MarR-WT cells were grown with 0.03% arabinose and pMPM-MarR-G95S cells were grown without arabinose (to produce less G95S than WT), the repression of mar-lacZ in the absence of ligand became about equal for the two MarRs; nevertheless, G95S still remained resistant to salicylate and sensitive to plumbagin (Fig. 2) . This suggested that the G95S MarR was truly resistant to salicylate. One explanation to reconcile these data with those of Duval et al. (2013) is that the G95S mutation may not affect binding of ligands to MarR; rather, a putative inactivating conformational change(s) in MarR normally caused by salicylate or 2,4-dinitrophenol binding may be blocked in the G95S mutant, while a similar conformational change caused by plumbagin binding is not blocked. Figure 3 shows the location in the MarR structure of residues involved in inactivation of MarR by ligands. They are categorized approximately according to the ligand specificity observed in Table 2 . It is clear that many of the mutations, including most of those collected via tetracycline (see Data S1 for further details). Synthesis of WT MarR was induced by 1/50 dilution into the same medium containing 0.03% arabinose, while G95S MarR received no arabinose. After 2.5 h, ligand was added (no ligand, none; 2000 lM salicylate, SAL; or 16 lM plumbagin, PLU) and growth was continued for 1.25 h. The y-axis (LacZ) values are as described in Fig. 1 and represent the fraction of mar promoters untitrated by MarR. Averages (with SD) are from two independent experiments. random mutagenesis (and selected for salicylate resistance), are concentrated in a helix 1 (a1), at residues 19, 20, 21, 22, 25, 26, and 29 . Although the first part of this helix (through residue 21) is involved in dimerization (Alekshun et al., 2001) , our mutations there, with the exception of R16A and H19A, did not notably affect MarR function as a repressor (Fig. 1) . The rest of a1 is part of the hinge linking the dimerization domain to the putative DNA-binding domain (Alekshun et al., 2001) . The other residues affecting response to ligand are located either in a2 (most of these were chosen by predicted structural homology with MTH313: residues 43, 44, 47, 48, and 50) or in b3 of the wing (residue 95). Many of these residues lie not far from the large pocket between the two subunits of MarR; such a cavity is typical of the MarR structural family and is approximately where the single salicylate binds to ST1710, a MarR structural homolog of unknown function from the archaeon Sulfolobus tokodaii (Kumarevel et al., 2008) , and where the ArmR peptide binds to inactivate the Pseudomonas structural homolog MexR (Wilke et al., 2008 ). An inspection of the unpublished structure of the MarR structural family member Salmonella virulence regulator SlyA with salicylate (Protein Data Bank 3DEU) using Swiss PDB Viewer reveals that one salicylate lies near the middle of a1 and the other lies near the first part of a5. The structure of the Staphylococcus epidermidis biofilm regulator TcaR shows eight salicylate binding sites located either within the dimerization domain or in the hinge region; many of these sites may be nonspecific (Chang et al., 2010) . The conformation of some MarR structural homologs is greatly altered by ligand (Saridakis et al., 2008; Wilke et al., 2008; Chang et al., 2010; Dolan et al., 2011) , but for others, any change is small or unobserved (Kumarevel et al., 2008) .
Location of mutant residues in MarR structure
Recently, unpublished structures of a Staphylococcus aureus protein of unknown function called 'MarR' have appeared: Protein Data Bank 4EM2, with five scattered salicylate molecules, and 4EM0, with a single salicylate near the wing in the putative DNA-binding domain plus one kanamycin near the hinge region. No dramatic changes appear to be caused by these ligands when compared with the unliganded structure 4EM1. A new unpublished structure of E. coli MarR obtained in the absence of salicylate at 2.6 A resolution (3VOE) is similar (RMS 1.09 A as determined using Swiss PDB Viewer) to the original 2.3 A structure with salicylate (1JGS; Alekshun et al., 2001) , although in 3VOE, unlike in 1JGS, the structures of the two monomers are slightly different (RMS 0.78). None of the residues identified in the present study are located in regions of the largest difference between 1JGS and 3VOE. Fig. 3 . MarR structure showing locations of residues affecting response to ligands. The drawing was made using Swiss PBD Viewer based on the structure of MarR previously described (Alekshun et al., 2001) . The orientation is similar to that of Fig. 1b of that work. One monomer of the dimer is yellow, and the other is light blue. All relevant residues along the backbone in the yellow monomer are numbered in black. Most relevant residues in the other (light blue) monomer are numbered in blue, omitting several in helix a1' for clarity. Helices a1 and a2 (yellow monomer) and a1' and a2' (light blue monomer) are labeled, as are the amino (N, N') and carboxy (C, C') termini, respectively. The ribbon backbone is color-coded for ligand resistances greater than fivefold greater than WT as follows: black, all three ligands; red, salicylate and 2,4-dinitrophenol; green, 2,4-dinitrophenol with or without low plumbagin; dark blue, plumbagin only.
It is possible that some of the mutations we studied may reduce ligand-mediated inactivation of MarR via altering the secondary or tertiary structure of MarR rather than by directly changing a group involved in ligand binding per se. Such mutations might only indirectly affect the binding site or might prevent a conformational change in MarR that normally results from ligand binding.
MarR from other enteric species
The amino acid sequence of E. coli MarR differs by only two residues (none of interest here) from the consensus MarR sequence of the PRK11512 Protein Cluster (Klimke et al., 2009 ). This cluster (see Figs S2 and S3) comprises MarR proteins whose primary amino acid sequences are 82-98% identical, representing seven genera of Enterobacteriaceae that have a marRAB operon (Citrobacter, Cronobacter, Enterobacter, Escherichia, Klebsiella, Salmonella, and Shigella). We have now shown that inactivation of E. coli MarR by three different ligands was reduced by mutations near the central cavity and hinge region (a1 and a2) of MarR, confirming and amplifying our earlier conclusions . Three distinct but overlapping regions of MarR were found for the three ligands. These results likely apply to all seven genera. 
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